Profile data is unavailable for this security.
About the company
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
- Revenue in INR (TTM)568.09bn
- Net income in INR104.93bn
- Incorporated1993
- Employees43.00k
- LocationSun Pharmaceutical Industries LtdSun House, CTS No. 201 B/1,, Western ExpMUMBAI 400063IndiaIND
- Phone+91 2 243244324
- Fax+91 2 243244343
- Websitehttps://sunpharma.com/
Mergers & acquisitions
| Acquired company | SUNPHARMA:NSI since announced | Transaction value |
|---|---|---|
| Checkpoint Therapeutics Inc | 5.84% | 292.69m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 850.58bn | 27.00k | 47.98 | -- | 31.77 | 6.14 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 910.34bn | 27.92k | 18.43 | -- | 14.99 | 3.49 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Lupin Ltd | 261.51bn | 46.45bn | 1.01tn | 19.98k | 20.25 | -- | 16.78 | 3.84 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.06tn | 26.94k | 18.98 | -- | 14.12 | 3.04 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.08tn | 30.31k | 23.67 | -- | 19.32 | 3.79 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Torrent Pharmaceuticals Ltd | 127.42bn | 22.72bn | 1.38tn | 16.11k | 60.76 | -- | 44.75 | 10.83 | 67.12 | 67.12 | 376.38 | -- | -- | -- | -- | 7,910,902.00 | -- | 9.54 | -- | 14.72 | 75.64 | 72.56 | 17.83 | 14.14 | -- | 16.34 | -- | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Divi's Laboratories Ltd | 103.14bn | 24.79bn | 1.64tn | 18.30k | 66.01 | -- | 55.91 | 15.88 | 93.45 | 93.45 | 388.82 | -- | -- | -- | -- | 5,636,066.00 | -- | 15.81 | -- | 17.33 | 61.65 | 55.90 | 24.04 | 25.82 | -- | -- | -- | 35.19 | 19.31 | 11.65 | 36.94 | 9.74 | 3.98 | 13.40 |
| Sun Pharmaceutical Industries Ltd | 568.09bn | 104.93bn | 4.07tn | 43.00k | 38.85 | -- | 30.38 | 7.17 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 101.24m | 4.22% |
| SBI Funds Management Ltd.as of 31 Jan 2026 | 43.34m | 1.81% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 41.35m | 1.72% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 25.60m | 1.07% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 23.34m | 0.97% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 22.76m | 0.95% |
| GQG Partners LLCas of 31 Dec 2025 | 22.20m | 0.93% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Dec 2025 | 20.65m | 0.86% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jan 2026 | 18.75m | 0.78% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 05 Feb 2026 | 18.65m | 0.78% |
